ALFA Finder| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 32.2 | 14.4 | 14.8 |
| Other income | 0.1 | 0.0 | 0.1 |
| Total income | 32.3 | 14.4 | 14.9 |
| Profit before exceptional items & tax | 4.0 | 2.4 | 2.4 |
| Profit before tax | 4.0 | 2.4 | 2.4 |
| Net profit | 2.9 | 1.7 | 1.8 |
| Operating margin | 12.4% | 16.7% | 16.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +61.10% |
|---|---|
| Net profit, quarter on quarter | +70.60% |
| Revenue, year on year | +117.60% |
BSE results filing, BSE: 544529. Figures extracted from the filing.
Aptus Pharma Ltd: key numbers
- Share price
- ₹480.00
- Market cap
- ₹823.2 Cr
- Revenue (annual)
- ₹46.57 Cr
- Net profit (annual)
- ₹4.62 Cr
- P/E (TTM)
- 178.2×Sector 43.8×
- Promoter holding
- 72.89%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aptus Pharma Ltd
All →Aptus Pharma Preferential Issue
Aptus Pharma got BSE in-principle approval for a preferential issue of 15,99,270 shares at a minimum Rs. 280 each. The issue is worth about Rs. 44.78 Crore.
- Value
- ₹44.78 Cr
Aptus Pharma Investor Presentation: Key Takeaways
H1 FY27 revenue ₹48.92 Cr, EBITDA ₹7.68 Cr (15.7% margin), PAT ₹5.07 Cr; revenue exceeds full FY26 (₹46.57 Cr). Trading-heavy model with rising receivables and negative operating cash flow.
Aptus Pharma H1 FY27 Results: Net Profit ₹5.1 Cr, Up 200.0% YoY
Aptus Pharma Ltd reported revenue from operations of ₹48.9 Cr (+239.6% YoY) and net profit of ₹5.1 Cr (+200.0% YoY) for H1 FY27.
- Key figure
- Net profit ₹5.1 Cr · +200.0% YoY
Aptus Pharma Other Announcement
Aptus Pharma Limited submitted the Regulation 74(5) compliance certificate for the quarter and half-year ended 30th September 2026, as received from its registrar.
Aptus Pharma Annual General Meeting
Aptus Pharma Ltd issued a corrigendum to its 16th AGM notice regarding inadvertent errors in the explanatory statement for item no. 3.
Aptus Pharma Fund Raise of ₹44.88 Cr
Aptus Pharma Limited's Board has approved raising ₹44.88 Crore through a preferential equity issue. Funds will support manufacturing capacity expansion, working capital, and Pan-India growth initiatives.
- Value
- ₹44.88 Cr
- Execution
- 36 months